期刊
CONTEMPORARY CHALLENGES IN AUTOIMMUNITY
卷 1173, 期 -, 页码 712-720出版社
WILEY-BLACKWELL
DOI: 10.1111/j.1749-6632.2009.04804.x
关键词
rituximab; juvenile systemic lupus erythematosus; thrombocytopenia; lupus nephritis; B-cell depletion
Rituximab (RTX) is currently used in many diseases, but its efficacy and safety in juvenile systemic lupus erythematosus (SLEj) is still unknown. In this chapter we present four case reports of children treated with RTX: three SLE and one immune thrombocytopenic purpura (ITP). Two of the three SLEj patients had class IV lupus nephritis (LN) and hematologic manifestations (pancytopenia), both reaching complete recovery of blood counts and improvement of LN with RTX treatment. Our third SLE patient had a severe onset with generalized microangiopathic manifestations in association with antiphospholipid antibodies and has been in remission for almost I year after RTX. However, our fourth case, a patient with ITP and renal failure, was treated with RTX without either hematologic or renal response.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据